Belkis Delgado
Internal Medicine · Miami Springs, FLNPI 1275770414
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Exeltis, USA Inc. accounts for 61.6% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 3 payments — averaging $89.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exeltis, USA Inc.$166
- Merck$104
Across 428 payments — averaging $10,183 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$818K
- Astrazeneca UK Limited$642K
- Gilead$550K
- E.r. Squibb & Sons, L.L.C.$369K
- AstraZeneca$337K
- Covis Pharma GmbH$310K
- plus $1.3M from 16 others
What the payments were for
- Food & beverage$270100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exeltis, USA Inc. | 2 | $166 |
| Merck | 1 | $104 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$270 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 82 | $41,093 |
| XareltoRivaroxaban | 50 | $26,922 |
| EliquisApixaban | 19 | $10,818 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $10,198 |
| EntrestoSacubitril/Valsartan | 12 | $7,767 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $6,513 |
| Insulin Aspart Prot Mix 70-30Insulin Aspart Prot/Insuln Asp | 21 | $4,903 |
| Novolog FlexpenInsulin Aspart | 20 | $3,214 |
| Nifedipine ErNifedipine | 26 | $2,248 |
| Insulin Aspart FlexpenInsulin Aspart | 13 | $1,933 |
| LantusInsulin Glargine,hum.Rec.Anlog | 15 | $1,320 |
| Unifine PentipsPen Needle, Diabetic | 51 | $1,101 |
| Metoprolol Succinate | 32 | $1,026 |
| Atorvastatin Calcium | 118 | $958 |
| Levothyroxine Sodium | 38 | $808 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Miami Springs
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.